Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects. * Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment. * The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301601PRIMZONEFULLFEED9837223) on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.